CTLA4 and neoplasm: This suggests the possibility of a systemic activation of a functional anti-tumor response upon tbLN-directed CTLA4 blockade, hinting at a possibility of optimal ICB regimen (multi-drug and/or multi-site or multi-dosed) being potent enough to induce a complete remission.